ADHD

>

Latest News

Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan
Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan

November 25th 2025

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.

How Neurodivergent Adults View Neurodiversity Terminology: Findings From a Large UK Survey
How Neurodivergent Adults View Neurodiversity Terminology: Findings From a Large UK Survey

November 18th 2025

Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care / image credit: ©Joel bubble ben/AdobeStock
Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care

November 4th 2025

ADHD Stimulant Use Raises Risk of Cardiomyopathy in Young Adults: Daily Dose / image credit: ©New Africa/AdobeStock
ADHD Stimulant Use Raises Risk of Cardiomyopathy in Young Adults: Daily Dose

April 10th 2024

Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy / Image credit: ©Alex DiStasi/AdobeStock
Young Adults Prescribed ADHD Stimulants May Face Higher Risk of Cardiomyopathy

April 1st 2024

More News

Site Logo

Overdoses of ADHD Drugs Lead to Many ER Visits

June 1st 2006

ATLANTA ? Stimulants used to treat attention deficit-hyperactivity disorder (ADHD) that are accidentally overdosed or trigger adverse reactions lead to more than 3,000 emergency room visits a year, estimate CDC researchers.

<12
© 2025 MJH Life Sciences

All rights reserved.